Design and Characterization of Prodrug-like Inhibitors for Preventing Glutamate Efflux through Reverse Transport

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Glutamate transporters regulate extracellular glutamate levels in the brain, crucial for neuronal function.
• Elevated glutamate can cause neurodegeneration, particularly during energy deprivation (e.g., ischemic stroke).
• Current strategies focus on managing glutamate levels, but preventing reverse transport-mediated release is key.

Purpose of the Study:

• To develop and validate novel prodrug inhibitors of excitatory amino acid transporters (EAATs).
• To demonstrate the efficacy of these prodrugs in preventing glutamate efflux via EAAT reverse transport.
• To explore a new therapeutic approach for preventing glutamate-induced neuronal cell death.

Main Methods:

• Synthesis of acetoxymethyl (AM) ester prodrug derivatives of EAAT inhibitors.
• Utilizing a fluorescent prodrug (TAOA AM ester) for cellular uptake studies.
• Employing electrophysiology and fluorescence assays (iGluSnFR sensor) to measure glutamate release.

Main Results:

• AM ester prodrugs efficiently permeate cell membranes and are activated intracellularly.
• Inhibitors effectively block K+-induced glutamate efflux mediated by EAAT reverse transport.
• The novel prodrug approach demonstrated efficacy in both model cell systems and human astrocytes.
• Glutamate uptake under physiological conditions remained operational.

Conclusions:

• AM ester prodrugs offer a promising strategy to inhibit pathological glutamate release by reverse transport.
• This method has potential applications in preventing neurodegeneration associated with conditions like ischemic stroke.
• The approach selectively targets harmful glutamate release, preserving normal physiological function.